Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
Open Access
- 1 January 2016
- journal article
- case report
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 55 (21) , 3151-3153
Abstract
This is the first report in which crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, reduced an atypical carcinoid tumor with ALK rearrangement. A 70-year-old man developed a tumor in the left lung and multiple metastases to the lung and brain. The pathology of transbronchial biopsied specimens demonstrated an atypical carcinoid pattern. Combined with immunohistochemical findings, we diagnosed the tumor as atypical carcinoid. ALK gene rearrangement was observed by both immunohistochemical (IHC) and fluorescence in situ hybridization. He was treated with chemotherapy as first-line therapy, however, the tumor did not respond to chemotherapy. Thereafter, he was treated with crizotinib, which successfully reduced the tumors.Keywords
This publication has 7 references indexed in Scilit:
- A Case of Atypical Carcinoid: Harboring Variant 3a/b EML4–ALK RearrangementJournal of Thoracic Oncology, 2015
- A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor CrizotinibJournal of Thoracic Oncology, 2014
- An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion geneLung Cancer, 2013
- Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinomaJournal of Clinical Pathology, 2013
- First Case of Combined Small-Cell Lung Cancer with Adenocarcinoma Harboring EML4 - ALK Fusion and an Exon 19 EGFR Mutation in Each Histological ComponentJournal of Thoracic Oncology, 2012
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Treatment and prognosis in bronchial carcinoids involving regional lymph nodesThe Journal of Thoracic and Cardiovascular Surgery, 1994